Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mistabron in the intensive care unit

J Van De Walle, P Lauwers, H Adriaensen

    Acta Anaesthesiologica Belgica
    |January 1, 1976
    PubMed
    Summary

    Mistabron, a novel mucolytic agent, eases expectoration and prevents lung complications in intensive care patients. This new drug offers advantages over older mucolytic treatments for tracheobronchial secretions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Reversible Calcineurin Inhibitor-associated Sensorimotor Polyneuropathy in a Lung Transplant Recipient: A Case Report.

    International journal of organ transplantation medicine·2022
    Same author

    Erratum: Spectroscopic Quadrupole Moments in ^{96,98}Sr: Evidence for Shape Coexistence in Neutron-Rich Strontium Isotopes at N=60 [Phys. Rev. Lett. 116, 022701 (2016)].

    Physical review letters·2016
    Same author

    TNM-Classification for Lung Cancer: From the 7(th) to the 8(th) Edition.

    Acta chirurgica Belgica·2016
    Same author

    Spectroscopic Quadrupole Moments in {96,98}Sr: Evidence for Shape Coexistence in Neutron-Rich Strontium Isotopes at N=60.

    Physical review letters·2016
    Same author

    Aortic Dissection Limited to Abdominal Aorta: an Underrecognized Entity?

    Acta chirurgica Belgica·2015
    Same author

    Preclose Percutaneous Endurant™ Endografting with the Proglide™ Device: a Safe and Feasible Combination.

    Acta chirurgica Belgica·2015

    Area of Science:

    • Pharmacology
    • Intensive Care Medicine
    • Respiratory Medicine

    Background:

    • Tracheobronchial secretions pose significant challenges in intensive care.
    • Existing mucolytic agents have limitations in efficacy and patient tolerance.
    • Novel therapeutic agents are needed to improve airway clearance and reduce pulmonary complications.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Mistabron as a mucolytic agent.
    • To compare the advantages of Mistabron over older mucolytic agents.
    • To assess the impact of Mistabron on expectoration and the incidence of lung complications in intensive care settings.

    Main Methods:

    • Clinical application of Mistabron in patients with tracheobronchial secretions.
    • Observational assessment of expectoration ease.
    • Evaluation of preventive administration for lung complication incidence.
    • Comparison with historical data or concurrent use of older mucolytic agents (details not specified in abstract).

    Main Results:

    • Mistabron facilitates easier expectoration in patients.
    • Preventive administration of Mistabron significantly reduces the incidence of lung complications.
    • Mistabron demonstrates advantages compared to older mucolytic agents (specific advantages not detailed).

    Conclusions:

    • Mistabron is an effective mucolytic agent for patients with tracheobronchial secretions.
    • Its use in intensive care medicine is associated with improved airway clearance and reduced pulmonary morbidity.
    • Mistabron represents a valuable therapeutic option for managing respiratory secretions and preventing complications.

    Related Experiment Videos